Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap

Cancers

Anna Halama¹  Karsten Suhre¹ 

[1] Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Doha 24144, Qatar;

关键词: cancer;    metabolism;    glutamine metabolism;    cancer treatment;    glutaminolysis inhibition;    drug resistance;   

DOI  :  10.3390/cancers14030553

来源: DOAJ

【 摘 要 】

Tumor growth and metastasis strongly depend on adapted cell metabolism. Cancer cells adjust their metabolic program to their specific energy needs and in response to an often challenging tumor microenvironment. Glutamine metabolism is one of the metabolic pathways that can be successfully targeted in cancer treatment. The dependence of many hematological and solid tumors on glutamine is associated with mitochondrial glutaminase (GLS) activity that enables channeling of glutamine into the tricarboxylic acid (TCA) cycle, generation of ATP and NADPH, and regulation of glutathione homeostasis and reactive oxygen species (ROS). Small molecules that target glutamine metabolism through inhibition of GLS therefore simultaneously limit energy availability and increase oxidative stress. However, some cancers can reprogram their metabolism to evade this metabolic trap. Therefore, the effectiveness of treatment strategies that rely solely on glutamine inhibition is limited. In this review, we discuss the metabolic and molecular pathways that are linked to dysregulated glutamine metabolism in multiple cancer types. We further summarize and review current clinical trials of glutaminolysis inhibition in cancer patients. Finally, we put into perspective strategies that deploy a combined treatment targeting glutamine metabolism along with other molecular or metabolic pathways and discuss their potential for clinical applications.

【 授权许可】

Unknown